(Q37780606)

23 August 2017

1 reference

title

Challenges and opportunities for drug discovery in psychiatric disorders: the drug hunters' perspective (English)

1 reference

23 August 2017

1 reference

Erik H F Wong

1

1 reference

23 August 2017

Frank Yocca

series ordinal

2

1 reference

23 August 2017

Mark A Smith

series ordinal

3

1 reference

23 August 2017

Chi-Ming Lee

series ordinal

4

1 reference

23 August 2017

publication date

18 August 2010

1 reference

The International Journal of Neuropsychopharmacology

23 August 2017

published in

1 reference

23 August 2017

volume

13

1 reference

23 August 2017

issue

9

1 reference

23 August 2017

page(s)

1269-1284

1 reference

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The complexity of the GABAA receptor shapes unique pharmacological profiles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Dose-dependent decrease of activation in bilateral amygdala and insula by lorazepam during emotion processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Animal models of mood disorders: Recent developments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Excitotoxicity, apoptosis and neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Assessing antidepressant activity in rodents: recent developments and future needs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Epigenetic mechanisms in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Assessing the economic costs of serious mental illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The current state, challenges and perspectives of MR-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

How can EEG/MEG and fMRI/PET data be combined?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

C2C12 myoblast/osteoblast transdifferentiation steps enhanced by epigenetic inhibition of BMP2 endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Discovering endophenotypes for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Antidepressant drug action: a neuropsychological perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Antidepressant effects of ketamine in depressed patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The endophenotype concept in psychiatry: etymology and strategic intentions

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

HPA axis reactivity: a mechanism underlying the associations among 5-HTTLPR, stress, and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Pharmacoepigenetics: its role in interindividual differences in drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Early integration of pharmacokinetic and dynamic reasoning is essential for optimal development of lead compounds: strategic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Capacity for 5-HT1A-mediated autoregulation predicts amygdala reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The role of positron emission tomography in pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

DISC-1 Leu607Phe alleles differentially affect centrosomal PCM1 localization and neurotransmitter release

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

[3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Glycine modulates [3H]MK-801 binding to the NMDA receptor in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Sites for Antagonism on the N-Methyl-D-Aspartate Receptor Channel Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Preliminary report of a simple animal behavior model for the anxiolytic effects of benzodiazepines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The role of imaging in proof of concept for CNS drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

From synapse to nucleus: novel targets for treating depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The role of the nucleus accumbens and rostral anterior cingulate cortex in anhedonia: integration of resting EEG, fMRI, and volumetric techniques

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Antidepressant actions of histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

From magic bullets to designed multiple ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Bringing order to the glutamate chaos in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Criteria for validating mouse models of psychiatric diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Lessons from 60 years of pharmaceutical innovation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Simultaneous EEG-fMRI: perspectives in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Gene-wide analyses of genome-wide association data sets: evidence for multiple common risk alleles for schizophrenia and bipolar disorder and for overlap in genetic risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Specific [3H]phencyclidine binding in rat central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The effectiveness of multi-target agents in schizophrenia and mood disorders: Relevance of receptor signature to clinical action

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Visualizing the drug target landscape

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Intermediate phenotypes and genetic mechanisms of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

What's atypical about atypical antipsychotic drugs?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Cingulate function in depression: a potential predictor of treatment response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Novel drugs and therapeutic targets for severe mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Finding the missing heritability of complex diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Correspondence of event-related potential tomography and functional magnetic resonance imaging during language processing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Epigenetic regulation in psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The moderation by the serotonin transporter gene of environmental adversity in the etiology of depression: 2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Fortnightly review: drug treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

A pathophysiological paradigm for the therapy of psychiatric disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

21 January 2018

The benzodiazepine story

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Realistic expectations of prepulse inhibition in translational models for schizophrenia research

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

New approaches to antidepressant drug discovery: beyond monoamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Safety of sumatriptan in pregnancy: a review of the data so far.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The CRF system, stress, depression and anxiety-insights from human genetic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Clinical implications of genetic variation in the serotonin transporter promoter region: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Akt/GSK3 signaling in the action of psychotropic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Human and animal studies of schizophrenia-related gating deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Common genetic determinants of schizophrenia and bipolar disorder in Swedish families: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

3HMK-801 Binding to N-Methyl-d-Aspartate Receptors Solubilized from Rat Brain: Effects of Glycine Site Ligands, Polyamines, Ifenprodil, and Desipramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

A comparison of the effects of a subtype selective and non-selective benzodiazepine receptor agonist in two CO(2) models of experimental human anxiety.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Using positron emission tomography to facilitate CNS drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Towards understanding the schizophrenia code: an expanded convergent functional genomics approach.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Can the pharmaceutical industry reduce attrition rates?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Innovation and greater probability of success in drug discovery and development -- from target to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Excitotoxicity and the NMDA receptor--still lethal after eight years

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

In vivo light-induced activation of neural circuitry in transgenic mice expressing channelrhodopsin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Neurocircuitry of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Evidence for a combined genetic effect of the 5-HT(1A) receptor and serotonin transporter genes in the clinical outcome of major depressive patients treated with citalopram

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

How can drug discovery for psychiatric disorders be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Predicting new molecular targets for known drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Controlled clinical comparison of paroxetine and fluvoxamine considering the serotonin transporter promoter polymorphism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Glycine transport inhibitors and the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Endophenotypes: bridging genomic complexity and disorder heterogeneity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Disruptive insights in psychiatry: transforming a clinical discipline

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Translating scientific opportunity into public health impact: a strategic plan for research on mental illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

Evidence of Disrupted Prepulse Inhibition in Unaffected Siblings of Bipolar Disorder Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

How to improve R&D productivity: the pharmaceutical industry's grand challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

2009 FDA drug approvals

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

Novel consortium to address shortfall in innovative medicines for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

The emergence of a new paradigm of pharmacogenomics

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

The advantage of using positron emission tomography in drug research

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

Intermediate phenotypes in schizophrenia genetics redux: is it a no brainer?

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

Impaired Repression at a 5-Hydroxytryptamine 1A Receptor Gene Polymorphism Associated with Major Depression and Suicide

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

Common polygenic variation contributes to risk of schizophrenia and bipolar disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

The state of innovation in drug development

1 reference

https://api.crossref.org/works/10.1017%2FS1461145710000866

7 January 2021

10.1017/S1461145710000866

Identifiers

DOI

1 reference

23 August 2017

1 reference